Dendreon (DNDN -14.4%) retests its lows for the day as the Street begins to weigh in on its Q1...


Dendreon (DNDN -14.4%) retests its lows for the day as the Street begins to weigh in on its Q1 miss and dismal Provenge sales numbers. Stifel Nicolaus cuts the shares to Sell, calling Provenge "hopeless," and saying the company is likely to burn through its cash long before it ever reaches breakeven, and faces the possiblity of bankruptcy before the end of FY14. Roth Capital also downgrades the stock to Sell as well.

From other sites
Comments (1)
  • Mikeinkc
    , contributor
    Comment (1) | Send Message
     
    Very disappointing. We all know the risks associated with the company itself and biotechs in general. I invested in the company after having read about all of the positives and change in management that was supposed to better Provenge sales. Thought the consumer add campaign may help but the mismanagement I keep reading about now is what makes this frustrating. Can't churn a profit when manufacturing costs are sky high and your products insanely high prices can't even make up that gap. I held on as long as I could.. time to take my lumps.
    9 May 2013, 03:54 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs